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 Introduction 
 Dysfunction of the cholinergic neurotransmitter sys-
tem is one of the characteristics of Alzheimer’s disease 
(AD)  [1] . Early studies considered cell death in the nucle-
us basalis of Meynert (NBM) to be the cause of the dimin-
ished level of acetylcholine (ACh)  [2, 3] . However, only 
a small proportion of cells in the NBM is actually lost in 
AD  [4] , and the observed lowered number of cholinergic 
markers is due to NBM atrophy rather than cell loss  [5] . 
Swaab argued that therapeutic strategies in AD could be 
directed towards stimulation of neurons to improve me-
tabolism and possibly reactivate impaired neurons in, e.g. 
the NBM  [5–7] . Accordingly, improved functioning 
might be established by stimulating the central nervous 
system exogenously with, e.g. enriched environment. 
 In enriched environments, the organism is typically 
subject to multisensory input  [8] . Unisensory stimulation 
techniques, such as bright light (visual sensory system) 
and tactile stimulation (somatosensory system) have 
yielded positive effects on several brain functions in mild 
cognitively impaired and demented patients  [9] . Walk-
ing, another type of somatosensory stimulation, resulted 
in an increased release of extracellular ACh in the hippo-
campus of rats  [10] . Somatosensory stimulation by means 
of peripheral electrical stimulation applied to the skin of 
rats showed an increased activity of the hippocampus and 
an elevated release of ACh in the hypothalamus  [11] . 
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 Abstract 
 In a number of studies, peripheral electrical nerve stimu-
lation has been applied to Alzheimer’s disease (AD) pa-
tients who lived in a nursing home. Improvements were 
observed in memory, verbal fl uency, affective behavior, 
activities of daily living and on the rest-activity rhythm 
and pupillary light refl ex. The aim of the present, ran-
domized, placebo-controlled, parallel-group clinical trial 
was to examine the effects of electrical stimulation on 
cognition and behavior in AD patients who still live at 
home. Repeated measures analyses of variance revealed 
no effects of the intervention in the verum group (n = 32) 
compared with the placebo group (n = 30) on any of the 
cognitive and behavioral outcome measures. However, 
the majority of the patients and the caregivers evaluated 
the treatment procedure positively, and applying the dai-
ly treatment at home caused minimal burden. The lack 
of treatment effects calls for reconsideration of electrical 
stimulation as a symptomatic treatment in AD. 
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 Somatosensory stimulation through transcutaneous 
electrical nerve stimulation (TENS) has been applied to 
AD patients in a number of placebo-controlled experi-
ments  [12–17] . In those studies, a small electrical current 
was applied to the skin of the upper back of AD patients. 
After application of the electrical stimulus 5 days a week 
for a period of 6 weeks, improvements were found in 
memory, verbal ﬂ uency, affective behavior, activities of 
daily living (ADL) and the rest-activity rhythm [for a re-
view, see  18] . A Japanese group replicated effects on cog-
nition and found a positive effect on pupillary light reﬂ ex 
 [19] . The latter is considered an indication that the cho-
linergic function has improved  [20] . Despite these en-
couraging ﬁ ndings, the positive effects of electrical stimu-
lation must be interpreted with caution because of the 
small sample sizes ranging from 6  [19] to 18  [14] .  
 In the studies described above, the participating AD 
patients lived in a nursing home. The research question of 
the present study was whether peripheral electrical nerve 
stimulation would also demonstrate positive effects on 
cognition and behavior of patients who still live at home. 
This randomized, placebo-controlled, parallel-group clin-
ical trial is unique since a family caregiver applied the 
treatment. Based on previous positive ﬁ ndings, it was hy-
pothesized that after a treatment period of 6 weeks the 
verum group would show improved functioning in cogni-
tion and behavior compared with the control group. 
 Materials and Methods 
 Participants 
 Participants were recruited from the Alzheimer Center of the 
VU University Medical Center, the Department of Neurology, Sint 
Lucas Andreas Hospital and the community home care agency in 
Amsterdam, The Netherlands. Men and women were eligible if 
they had a diagnosis of probable AD according to the NINCDS/
ADRDA criteria  [21] . A Mini-Mental State Examination (MMSE) 
 [22] score of 26 or lower and sufﬁ cient hearing and vision were re-
quired. In addition, it was essential that the AD patient was living 
at home with a partner or other family member who served as pri-
mary caregiver (the partner or other family member is further re-
ferred to as family caregiver). Patients with a diagnosis of dementia 
other than AD, cerebrovascular disease or clinical depression were 
excluded, as were patients who had a history of cerebral trauma, 
disturbances of consciousness, seizures, epilepsy or an infectious 
disease. Also, patients with a cardiac pacemaker were excluded be-
cause of reported interference between a pacemaker and an electri-
cal stimulator  [23] . 
 After the procedure of the study had been fully explained, writ-
ten informed consent was obtained from the patient and/or the 
family caregiver. The study was approved by the local medical eth-
ical committees and by the committee on research involving human 
subjects in The Hague, The Netherlands. 
 Study Design 
 In this 12-week, randomized, placebo-controlled, parallel-group 
study, assessment of cognition and behavior took place at baseline 
(pre), after the treatment period of 6 weeks (post) and following a 
treatment-free period of 6 weeks (delayed). Additionally, a ques-
tionnaire covering applicability and efﬁ cacy of the treatment ac-
cording to the patient and caregiver was administered after treat-
ment. 
 Intervention 
 A standard commercially available TENS device (Premier 10s ® , 
Xytron Medical, Apeldoorn, The Netherlands) was used. It pro-
duced biphasic square pulses with a width of 100   s, applied in 
bursts of 9 pulses with a frequency of 160 Hz and a repetition rate 
of 2 Hz. Self-adhesive medical electrodes for electrical stimulation 
(XyTrode ® , Xytron Medical) were placed on the back at the ﬁ rst 
thoracic vertebra, lateral to the spine. The intensity of the stimuli 
was set at a level that produced painless, visible muscular twitches. 
These stimulation parameters were chosen to optimally target af-
ferent nerve ﬁ bers, i.e. A-Beta, A-Delta and C-ﬁ bers, which convey 
the pulses to subcortical and cortical areas [for more details, see 
 13] . The family caregiver applied the treatment for 30 min a day, 
7 days a week, for a period of 6 weeks. To minimize interference 
in the daily routine of the participants, the patient and family care-
giver were free to decide what time of the day they would admin-
ister the treatment. 
 Randomization and Blinding 
 Participants were allocated to either the verum or the placebo 
treatment using simple randomization by tossing an unbiased coin. 
Participants assigned to the verum group received verum treat-
ment, whereas participants in the placebo group were told that the 
stimulator was working as soon as the green light was blinking with-
out current being applied. To maintain the participants’ blindness, 
and because they knew there was a verum and a placebo condition, 
the two groups were informed as follows. The verum group was told 
that different pulse frequencies were applied to both groups: one 
frequency that might have the desired effect and one that, on theo-
retical grounds, was unlikely to be effective. Hence, patients who 
received the verum treatment, felt the stimulus and the caregiver 
would observe muscle contraction, would still be under the assump-
tion that they might be treated with noneffective stimuli. The par-
ticipants in the placebo group were also told that we were applying 
different pulse frequencies in two groups, but that the pulse fre-
quencies were in a range that could not be perceived. The neuro-
psychologist who instructed the participants about the use of the 
electrical stimulator (K.R.A.V.D), was not blinded to group alloca-
tion because a different instruction was required when explaining 
the use of the electrical stimulator to the verum and placebo groups. 
Patients, family caregivers and test administrators were blinded to 
group allocation. 
 Cognitive Measures 
 Digit Span, a subtest of the Wechsler Memory Scale  [24] , con-
sists of a Forward and a Backward condition. The Forward condi-
tion served as a measure of attention for verbally presented stimu-
li and the Backward condition was used as a measure of working 
memory for verbally presented stimuli. The score for each condi-
tion is the number of correctly reproduced sequences. 
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 Visual Memory Span  [24] is the nonverbal equivalent of the 
Digit Span test. The Forward and the Backward condition served 
as a measure of attention and working memory for visually pre-
sented stimuli, respectively. The score for each condition is the 
number of correctly reproduced sequences. 
 The Eight Words Test  of the Amsterdam Dementia Screening 
test  [25] was used to assess verbal episodic memory. The immediate 
recall score is the total number of correct words after 5 trials and is 
used as a measure of the patients’ ability to process and learn verbal 
stimuli. The delayed recall score is the total number of correctly re-
produced words after a delay of approximately 10 min, measuring 
active retrieval of information from verbal memory. The recogni-
tion score is the total of correct responses minus incorrect respons-
es, and measures recognition of the previously presented stimuli. 
 Face Recognition of the Rivermead Behavioural Memory test 
 [26] was used as a measure of visual, nonverbal long-term recogni-
tion memory. 
 Picture Recognition of the Rivermead Behavioural Memory 
test  [26] served as a measure of visual, verbal long-term recognition 
memory. 
 The Stroop Color Word test  [27] was used to obtain a measure 
of interference control, i.e. the ability to disregard an automated 
response. The interference score is computed by subtracting the 
correctly named colors in 45 s on the color card from the correctly 
named colors in 45 s on the color/word card. A high interference 
score is an indication of poor interference control. 
 Category Fluency test  was used to measure verbal ﬂ uency  [28] . 
Categories were animals and professions. The total score for each 
category is the number of correct words produced in 60 s. 
 Self-Report Questionnaires Assessing Emotional Status 
 The patients reported the status of their emotional condition 
using the following questionnaires that were administered by an 
interviewer.  
 The Geriatric Depression Scale (GDS)  [29] , a Dutch 30-item 
version, was administered to assess symptoms of depression. Be-
cause the sample in the present study included cases of severe AD 
and because of known limited validity and reliability of the GDS 
when administered to cognitively impaired populations  [30] , a se-
lection of 12 items was used to calculate the total score. The 12 
selected items make up the GDS-12R, a screening measure appro-
priate for use with older people in nursing and residential care set-
tings, including persons with cognitive impairment  [31] . Internal 
reliability of the GDS-12R was 0.81 and 0.78 for those patients 
with an MMSE score below 10  [31] . 
 The Philadelphia Geriatric Center Morale Scale (PGCMS)  [32] 
was administered to obtain a measure of subjective well-being. This 
17-item questionnaire is designed to measure dimensions of emo-
tional adjustment in people aged 70–90. The total score on the 17 
items is used as a measure of global life satisfaction. 
 Informant-Based Ratings of Functional and Emotional Status 
 The Philadelphia Geriatric Center Affect Rating Scale (PG-
CARS)  [33] is an observation scale designed to rate affective states 
in dementia. 
 The Dutch Behavioral Observation Scale for Psychogeriatric 
Inpatients  (GIP-28)  [34] was used to assess psychiatric symptoms 
in 28 items. This shortened version is a modiﬁ cation of the original 
82-item GIP  [35] that is based on the Physical and Mental Impair-
ment-of-Function Evaluation  [36] . Three symptom dimensions 
were used as dependent variables: negative symptoms, cognitive 
symptoms and mood/affective symptoms  [37] . 
 ADL is a list of selected items obtained from Katz et al.  [38] 
that are part of a larger patient-informant interview  [39] . It was 
used as a measure of functional independence. 
 Applicability and Efﬁ cacy Questionnaire 
 In a questionnaire designed by the authors, applicability and 
efﬁ cacy of the treatment according to the patient and family care-
giver were assessed. Part A consists of questions for the patient 
receiving the treatment and includes 2 subscales. (1) ‘Perceived 
burden’, ranging from 0 (no burden) to 12 (highest burden), and
(2) ‘Perceived efﬁ cacy’, ranging from 0 (no beneﬁ t) to 4 (most ben-
eﬁ t). Part B consists of items for the family caregiver and includes 
4 subscales. (1) ‘Difﬁ culties using the apparatus’ ranging from 0 (no 
burden) to 8 (highest burden); (2) ‘Perceived burden for the family 
caregiver’ ranging from 0 (no burden) to 8 (highest burden);
(3) ‘Perceived burden for the patient’ ranging from 0 (no burden) 
to 12 (highest burden), and (4) ‘Perceived efﬁ cacy’ ranging from 0 
(no beneﬁ t) to 4 (most beneﬁ t). 
 Statistical Analysis 
 Complete case method was used in which all patients with a 
missing response on an outcome variable were excluded from anal-
ysis regarding that variable. Comparisons of group characteristics 
were made using independent sample t tests for normally distrib-
uted data and Mann-Whitney U tests for categorical data. Depen-
dent variables that were not normally distributed were transformed 
using square root or log transformation. For purpose of clarity, all 
means printed in the tables are the original values. To determine 
treatment effects, dependent variables were subject to repeated uni-
variate analyses of variance (ANOVAs), employing transformed 
scores when applicable, with group (two levels: verum and placebo) 
as between subjects factor and time as within-subject factor (3 lev-
els: pre, post and delayed). Treatment effects were hypothesized to 
emerge after the treatment period; therefore, post vs. pre contrasts 
were computed. To investigate if any effects lasted when the treat-
ment was discontinued, delayed vs. pre contrasts were computed. 
Group differences on the applicability and efﬁ cacy questionnaire 
were analyzed using ANOVAs. To compensate for the use of mul-
tiple comparisons, a signiﬁ cance level of 0.01 was applied. SPSS 
Base for Windows v11.5 was used for all analyses. 
 Results 
 Patient Characteristics 
 Of the 68 patients who were included and randomly 
allocated to either treatment group, 65 (96%) completed 
the study. Discontinuation during the treatment phase 
occurred only in the placebo group and was due to refused 
treatment (n = 1), stroke (n = 1) and a partner who sus-
tained an arm fracture (n = 1). An additional 3 cases were 
excluded from analysis because of missing data. Finally, 
62 patients (91%) entered the analysis phase. An over-
view of the progress through the different phases of the 
trial is given in  ﬁ gure 1 . 
 van Dijk/Scheltens/Luijpen/Sergeant/
Scherder 
 
 Dement Geriatr Cogn Disord 2005;19:361–368 364
 The two treatment groups were not signiﬁ cantly dif-
ferent with regard to sex, age, education and MMSE ( ta-
ble 1 ). In total, there were 39 men and 23 women; their 
mean age was 71.7 years (SD 8.0; range 52–87). Mean 
years of education was 10.5 (SD 3.6; range 6–20) and 
mean MMSE score at baseline was 15.2 (SD 6.9; range 
0–26). All patients lived with a partner/spouse or family 
member. 
 Treatment Effects 
 Cognitive Measures 
 Independent samples t tests indicated no signiﬁ cant 
differences between groups on cognitive measures before 
 Fig. 1. Flow diagram of the progress through 
the phases of the trial. 
 Table 1. Patient characteristics 
Verum
(n = 32)
Placebo
(n = 30)
Total
(n = 62)
Males/females 17/15 22/8 39/23
Age, years
Mean (SD) 71.0 (7.8) 72.5 (8.2) 71.7 (8.0)
Range 52–87 55–87 52–87
Education, years
Mean (SD) 10.3 (3.9) 10.7 (3.3) 10.5 (3.6)
Range 6–20 6–20 6–20
MMSE
Mean (SD) 15.7 (6.8) 14.7 (7.2) 15.2 (6.9)
Range 0–26 1–26 0–26
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treatment. Results of repeated measures ANOVAs sug-
gested no signiﬁ cant differences on any of the cognitive 
measures between groups after treatment ( table 2 ). 
 Self-Report Questionnaires Assessing Emotional 
Status 
 Groups did not differ on the GDS12R or PGCMS be-
fore the treatment period. Repeated measures ANOVAs 
revealed no signiﬁ cant differences between groups after 
treatment. 
 Informant-Based Ratings Assessing Functional and 
Emotional Status 
 Family caregivers of patients in the verum group and 
in the placebo group did not rate functional status on the 
ADL scale and emotional status on the PGCARS and 
GIP-28 differently. Repeated measures ANOVAs re-
vealed no effects of the intervention on any of the func-
tional and emotional measures based on the caregivers 
judgments ( table 3 ). 
 Table 2. Means, standard deviations and repeated ANOVA of the cognitive measures before treatment (pre), after treatment (post) and 
after a treatment free period (delayed) of the verum and placebo groups 
Verum Placebo ANOVA
pre post delayed pre post delayed pre vs. post pre vs. delayed
M SD M SD M SD M SD M SD M SD F d.f. p F d.f. p
Digit Span Forward 4.54 1.8 5.00 2.1 4.61 2.2 4.17 2.0 4.34 2.0 4.31 2.0 0.6 1, 55 0.45 0.0 1, 55 0.86
Digit Span Backward 3.25 1.9 3.36 1.7 3.29 1.8 3.41 2.2 3.28 1.8 3.14 1.9 0.5 1, 55 0.49 1.1 1, 55 0.30
Visual Memory Span Forward 3.89 1.7 3.79 2.1 4.18 2.1 4.28 2.1 4.00 2.2 3.90 2.5 0.3 1, 55 0.62 2.8 1, 55 0.10
Visual Memory Span  Backward 3.21 2.8 3.36 2.1 2.93 2.1 3.00 2.2 3.24 2.4 3.38 2.4 0.1 1, 55 0.79 9.3 1, 55 0.10
Eight Words Test
Immediate Recall 15.43 6.6 15.00 8.1 16.11 7.4 13.00 8.1 13.62 8.1 14.17 9.0 1.2 1, 55 0.28 1.7 1, 55 0.69
Delayed Recall 0.89 1.6 0.71 1.3 1.11 1.8 0.41 1.0 0.76 1.3 0.76 1.7 3.6 1, 55 0.06 0.0 1, 55 0.77
Cued Recall 7.86 5.7 8.14 5.1 7.43 5.0 5.07 5.7 6.07 5.5 6.59 6.2 0.3 1, 55 0.57 2.4 1, 55 0.12
Face Recognition 5.14 5.2 6.36 3.0 6.71 3.9 6.14 4.1 6.21 3.8 7.31 3.3 0.9 1, 55 0.34 0.0 1, 55 0.83
Picture Recognition 14.21 6.2 13.39 5.8 11.71 8.6 12.00 7.6 12.14 7.5 12.00 7.3 0.0 1, 55 0.97 0.3 1, 55 0.58
Stroop Interference 31.10 17.0 32.70 17.1 30.50 16.2 26.65 14.5 30.29 15.7 28.10 13.7 0.2 1, 35 0.68 0.2 1, 36 0.64
Verbal Fluency Animals 10.00 6.9 9.39 6.1 8.82 7.1 7.72 6.2 7.83 6.1 7.69 6.8 1.1 1, 55 0.31 2.2 1, 55 0.14
Verbal Fluency Professions 6.79 5.3 7.46 5.5 6.64 5.9 4.79 4.2 5.24 5.2 4.79 4.6 1.1 1, 55 0.30 0.0 1, 55 0.96
 
 Table 3. Means, standard deviations  and repeated ANOVA of the behavioral measures before treatment (pre), after treatment (post) 
and after a treatment free period (delayed) of the verum and placebo groups 
Verum Placebo ANOVA
pre post delayed pre post delayed pre vs. post pre vs. delayed
M SD M SD M SD M SD M SD M SD F d.f. p F d.f. p
GDS-12Ra 1.25 1.4 1.64 1.8 1.43 1.7 0.92 1.2 1.32 1.6 1.14 1.2 0.1 1, 54 0.92 0.6 1, 54 0.45
PGCMSb 13.32 2.9 13.04 3.7 13.04 3.5 14.21 3.3 14.50 3.8 14.39 3.4 0.7 1, 54 0.42 0.4 1, 54 0.42
PGCARS
Pleasureb 4.03 1.2 3.75 1.2 3.69 1.2 3.83 1.2 4.03 1.0 3.69 1.1 2.9 1, 59 0.09 0.4 1, 59 0.56
Angera 1.97 1.2 1.72 1.1 1.84 1.0 1.90 1.2 1.90 1.0 2.00 1.1 1.7 1, 59 0.19 1.3 1, 59 0.27
Anxietya 2.28 1.5 2.06 1.4 2.13 1.5 2.34 1.3 2.14 1.2 2.24 1.3 0.0 1, 59 0.98 0.0 1, 59 0.91
Sadnessa 2.00 1.1 2.19 1.1 2.06 1.2 1.97 1.5 1.93 1.0 1.86 1.1 0.7 1, 59 0.39 0.4 1, 59 0.54
Interestb 3.59 1.3 3.69 1.3 3.34 1.4 3.10 1.3 3.83 1.3 3.66 1.3 4.4 1, 59 0.04 6.0 1, 59 0.02
Contentb 4.19 0.8 4.03 0.9 3.94 0.8 4.17 0.9 4.48 0.7 4.24 0.9 3.7 1, 59 0.06 1.5 1, 59 0.23
GIP-28
Negative symptomsa 7.03 3.5 6.75 2.9 6.94 2.8 7.50 4.0 7.79 3.0 8.00 3.7 0.6 1, 59 0.44 0.5 1, 59 0.48
Cognitive symptomsa 12.75 5.2 10.37 4.3 10.97 5.6 12.66 5.6 9.93 6.1 12.00 6.3 0.2 1, 59 0.67 1.1 1, 59 0.31
Mood/affective symptomsa 5.69 5.1 3.44 4.9 3.78 5.3 5.10 5.3 3.41 4.1 3.52 4.4 1.2 1.59 0.28 1.1 1, 59 0.29
ADLa 7.38 6.6 7.78 6.5 8.00 6.7 8.21 6.8 8.52 7.8 10.03 9.2 2.1 1, 59 0.15 0.4 1, 59 0.56
a Low values are considered positive. b High values are considered positive.
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 Applicability and Efﬁ cacy of the Treatment 
 Questions for Patients 
 Patients from both the verum and the placebo group 
did not signiﬁ cantly differ on the subscales of the appli-
cability and efﬁ cacy questionnaire. Thus, burden caused 
by the treatment and perceived efﬁ cacy of the treatment 
were not rated differently by the two groups ( table 4 ). 
 The means ( table 4 ) show that the burden and per-
ceived efﬁ cacy was quite low in both groups. 
 Questions for Family Caregivers 
 Family caregivers who applied the real electrical stim-
ulus also did not score differently on any of the subscales 
compared with those who applied sham stimulation. 
 Mean scores indicate hardly any difﬁ culty using the 
apparatus, low burden and low perceived efﬁ cacy in both 
groups. 
 Discussion 
 Treatment Effects 
 We found that peripheral electrical nerve stimulation 
had no beneﬁ cial inﬂ uence on the measures of cognitive 
and behavioral functioning in patients in the verum group 
compared with the placebo group after a treatment period 
of 6 weeks. 
 These results differ from the positive outcomes ob-
served in previous studies using electrical stimulation in 
AD  [12–17, 19] , and the question rises how this discrep-
ancy can be explained. Firstly, the number of participat-
ing patients here is 3 times the number included in the 
earlier studies. The lack of treatment effects in the pres-
ent study could imply that the earlier ﬁ ndings observed 
in relatively small numbers of patients were not real treat-
ment effects. Secondly, the present study included pa-
tients at all stages of AD, ranging from mild to severe, 
with a lower mean level of cognitive functioning than pa-
tients in previous studies using electrical stimulation. Le 
Bars et al.  [40] observed a treatment effect of a ginko bi-
loba extract on, among others, the cognitive subscale of 
the Alzheimer’s Disease Assessment Scale, irrespective of 
the stage of dementia. However, an  improvement  was par-
ticularly observed in very mild to mild demented pa-
tients, whereas stabilization or hindering a further pro-
gression of the disease was characteristic for the more 
advanced stage of dementia. In other words, a treatment 
effect should not automatically be considered the same 
as an improvement in functioning. In addition, results 
from a recent review indicate that pharmacological treat-
ment in AD stabilizes cognitive functioning and enhanc-
es ADL  [41] . Thus, patient groups that are more homog-
enous with regard to disease severity may have generated 
different treatment effects than those reported here. A 
third difference between the current and former studies 
is the age of disease onset (it is earlier in the present study). 
There is ample evidence that early onset is associated 
with more severe cognitive impairment, more aggressive 
course of the disease, more AD pathology, greater neocor-
tical cholinergic cell loss and a higher prevalence of apo-
lipoprotein E  4  [42, 43] . Therefore, the number of pa-
tients with early onset AD included in this study, may 
have reduced average treatment effects. 
 Taken together, the lack of treatment effects in the 
present study with a considerable number of patients may 
question the treatment effects observed in earlier studies 
 Table 4. Means and standard deviations of scores on the applicability and efﬁ cacy questionnaire subscales of the 
verum and placebo groups 
Verum Placebo Total
M SD M SD M SD
Part A (questions for the patient)
Perceived burden 2.22 1.9 1.60 1.1 1.97 1.6
Perceived efﬁ cacy 1.10 1.4 0.77 1.3 0.97 1.3
Part B (questions for the family caregiver)
Difﬁ culties using the apparatus 1.54 1.3 1.70 1.6 1.61 1.4
Perceived burden for the family caregiver 1.22 1.3 1.26 1.4 1.24 1.3
Perceived burden for the patient 1.56 1.3 1.00 0.8 1.30 1.1
Perceived efﬁ cacy 1.13 1.3 1.26 1.2 1.19 1.2
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with fewer participants. However, patients’ characteris-
tics (level of cognitive functioning and age of onset of AD) 
differed between this study and previous studies. Perhaps 
the theory that stimulating the central nervous system 
improves metabolism and reactivates impaired neurons 
 [5–7] does not hold for AD patients in a more advanced 
stage and/or patients with early onset AD. This suggestion 
is supported by Geddes and Cotman  [44] who note that 
when neuropathology in AD is more severe, functional 
beneﬁ ts of plasticity become less certain. 
 A large replication study with AD patients in an ear-
lier phase of the disease might provide a more deﬁ nitive 
conclusion about the beneﬁ cial effect of peripheral elec-
trical nerve stimulation in AD. 
 Treatment Applicability 
 We also examined how the patients underwent the 
treatment and how the family caregiver experienced ap-
plying the treatment. Interestingly, the majority of the 
patients and the caregivers were very positive about the 
procedure, and applying the daily treatment was accom-
panied with minimal burden. 
 Several studies have focused on the effects of provid-
ing care to a demented relative and found an increased 
strain on psychological and physical health of the family 
caregiver  [45, 46] . Other studies report a positive gain 
from caregiving  [47, 48] or captured the caregivers’ expe-
rience in the term vigilance; operationalized as ‘supervis-
ing’ and ‘being there’  [49] . Another group found that 
when caregivers provided end-of-life care at home they 
showed faster recovery from depression and psychologi-
cal stress after death of their relatives than caregivers of 
patients who were institutionalized  [50] . Also, a study on 
nursing-home placement of cognitively impaired elderly 
who were cared for by their relatives, found that caregiv-
ers expressed a higher preference for institutionalization 
if he or she experienced less caregiving satisfaction  [51] . 
In sum, the present study is, to our knowledge, the ﬁ rst to 
show that an active role for the family caregiver is feasible 
in symptomatic treatment of a demented relative. 
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